Arcutis Biotherapeutics, Inc.
https://arcutis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcutis Biotherapeutics, Inc.
Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD
Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
China's Connect Eyes Partnerships To Globalize Dermatitis Biologic
Watch out Sanofi. US- and China-based Connect BioPharma is looking to position its novel biologic for atopic dermatitis to compete head-on with best-selling Dupixent both inside and outside China in an increasingly crowded space, says co-founder and CEO Wei Zheng in an exclusive interview with Scrip.
Arcutis’s Zoryve Succeeds In Second Phase III In Atopic Dermatitis
Immuno-dermatology specialist intends to submit the topical roflumilast to the US FDA during the first half of 2023, potentially adding an even larger indication to its approval for psoriasis.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
- Other Names / Subsidiaries
-
- Ducentis BioTherapeutics Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice